Protara Therapeutics (TARA) Interest Expenses (2013 - 2014)

Protara Therapeutics (TARA) has reported Interest Expenses for 14 consecutive years, with $8.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses rose 109.33% year-over-year to $8.8 million; the TTM figure through Mar 2026 stood at $8.8 million (up 109.33% YoY), while the FY2025 annual figure was $83.6 million, up 15.31% from the prior year.
• Interest Expenses grew to $8.8 million in Q1 2026 per TARA's latest filing, from $357000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $8.8 million in Q1 2026 and bottomed at $239000.0 in Q4 2023.
• Historically, Interest Expenses has averaged $2.5 million across 5 years, with a median of $1.4 million in 2023.
• On a YoY basis, Interest Expenses climbed as much as 2782.0% in 2022 and fell as far as 85.59% in 2022.
• Protara Therapeutics' Interest Expenses stood at $332000.0 in 2022, then decreased by 28.01% to $239000.0 in 2023, then jumped by 38.91% to $332000.0 in 2024, then rose by 7.53% to $357000.0 in 2025, then jumped by 2376.75% to $8.8 million in 2026.
• Business Quant data shows TARA's Interest Expenses at $8.8 million in Q1 2026, $357000.0 in Q4 2025, and $5.0 million in Q3 2025.